Larry Hoffman has served as our interim Chief Financial Officer since January 2024. Mr. Hoffman of Danforth Advisors, LLC is a senior life sciences financial executive with an extensive background in finance, Contract Research Organization (CRO) leadership, drug development, Securities and Exchange Commission (SEC) reporting, clinical operations, business restructuring, contract negotiation, corporate governance, taxation and fund raising. Since November 2021, Mr. Hoffman has been a member of Danforth Advisors, LLC providing executive financial services to several companies including Scynexis, Inc. (Nasdaq: SCYX) from November 2021 until October 2022. From February 2018 to October 2021, Mr. Hoffman was Chief Financial Officer of Sermonix Pharmaceuticals, Inc., a biopharmaceutical company. Prior to Sermonix, Mr. Hoffman worked as a consultant on a wide range of finance, tax, and contractual issues at Hoffman Consulting from 2012 to February 2018. He has more than 30 years of experience in financial leadership roles for private and public companies in industries including biotech, CRO and life sciences. Mr. Hoffman obtained a B.S. in Business Administration from La Salle University, a CPA license, a Master of Laws (LLM) in Taxation from Villanova University School of Law and a Juris Doctor from Temple University School of Law.